Monoamine Oxidases in Smoking Pregnant Women and Newborns
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00169390|
Recruitment Status : Completed
First Posted : September 15, 2005
Last Update Posted : March 19, 2015
Smoking substantially inhibits the activities of both monamine oxidase (MAO) A and B enzymes.
Aims of this study: to compare MAO activities and nicotine and cotinine in peripheral blood of smoking and nonsmoking pregnant women, in their placenta and in cord blood and relate them with the behavior of their newborns being observed during 48 hours after birth.
|Condition or disease|
|Smoking Pregnancy Newborn|
40 pregnant smoking and 40 pregnant nonsmoking women will be included at the end of the 2nd trimester.
Assessments: smoking characteristics, plasma cotinine, DHPG, DOPAC, 5HIAA concentrations reflecting MAOA activity and platelet MAOB activity will be measured just after inclusion (end of 2nd trimester), just before delivery in venous maternal blood and just after delivery in cord blood.
The newborns' behavior (wellbeing) will be assessed every 8 hour after birth for 2 days.
Comparisons will be made between smoking and nonsmoking women and their newborns.
|Study Type :||Observational|
|Actual Enrollment :||59 participants|
|Official Title:||Comparison of Monoamines Oxidases A and B Activities and the Metabolism of Nicotine in Smoking and Nonsmoking Pregnant Women and in Their Newborns. Evaluation of Their Effects on the Newborns' Behavior|
|Study Start Date :||March 2004|
|Actual Primary Completion Date :||November 2007|
|Actual Study Completion Date :||November 2007|
|pregnant non smokers|
- monoamine oxidase markers [ Time Frame: at birth ]
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00169390
|Study Chair:||Ivan Berlin, MD, PhD||Groupe Hospitalier Universitaire Pitié-Salpêtrière, Service de Pharmacologie and INSERM U677|